Vivos Therapeutics (VVOS) Common Equity (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Common Equity data on file, last reported at -$1.3 million in Q1 2026.

• Quarterly Common Equity fell 128.75% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (down 128.75% YoY) and the FY2025 annual result came in at -$1.5 million, down 119.49% from the prior year.
• Common Equity climbed to -$1.3 million in Q1 2026 per VVOS's latest filing, from -$1.5 million in the prior quarter.
• Across five years, Common Equity topped out at $21.0 million in Q1 2022 and bottomed at -$1.5 million in Q4 2025.
• The 5-year median for Common Equity is $4.6 million (2025), against an average of $5.4 million.
• The widest annual swing landed in 2024, when Common Equity jumped 16563.04%; it then tumbled 128.75% in 2026.
• Tracing VVOS's Common Equity over 5 years: stood at $4.8 million in 2022, then slumped by 91.44% to $411000.0 in 2023, then jumped by 1835.28% to $8.0 million in 2024, then tumbled by 119.49% to -$1.5 million in 2025, then rose by 18.26% to -$1.3 million in 2026.
• Per Business Quant, the three latest VVOS Common Equity figures stand at -$1.3 million (Q1 2026), -$1.5 million (Q4 2025), and $2.5 million (Q3 2025).

Peer Comparison